Ibrutinib updates from ASH 2016
What does the TOURMALINE-MM2 study tell us about the use of ixazomib in multiple myeloma?
Treatment landscape for high-risk multiple myeloma patients
Daratumumab shows remarkable benefit in relapsed or refractory multiple myeloma in the POLLUX trial
ASH 2015 highlights in multiple myeloma by Prof. Ola Landgren